Literature DB >> 15918143

Hepatocellular carcinoma: epidemiology, risk factors, and screening.

Morris Sherman1.   

Abstract

In this article, the epidemiology of hepatocellular carcinoma (HCC), risk factors for the development of HCC, and how these factors affect the decision about whether an individual should or should be entered into a screening program are considered. The factors determining the risk for HCC include age, male gender, and the nature of the underlying liver disease. In particular, cirrhosis is associated with a significant risk for HCC. However, in hepatitis B HCC also occurs in noncirrhotic liver. Decision analysis can be used to identify patients at greatest risk for HCC and who might be candidates for screening. Screening itself should be developed in a programmatic manner to ensure that appropriate target populations are identified, that appropriate screening tests are chosen, and that appropriate recall and enhanced follow-up are instituted for patients who have positive screening test results. Screening should be by ultrasonography at 4- to 12-month intervals. Patients with abnormal screening tests require additional investigation using computed tomography scanning, magnetic resonance imaging, or liver biopsy. Negative results do not exclude the possibility of cancer and further follow-up is necessary.

Entities:  

Mesh:

Year:  2005        PMID: 15918143     DOI: 10.1055/s-2005-871194

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  147 in total

Review 1.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

2.  Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system.

Authors:  Albert C Y Chan; Sheung Tat Fan; Ronnie T P Poon; Tan To Cheung; Kenneth S H Chok; See Ching Chan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-12-02       Impact factor: 3.647

3.  C-reactive protein genetic polymorphisms increase susceptibility to HBV-related hepatocellular carcinoma in a Chinese population.

Authors:  Qiliu Peng; Shan Ren; Xianjun Lao; Yu Lu; Xiaolian Zhang; Zhiping Chen; Xue Qin; Shan Li
Journal:  Tumour Biol       Date:  2014-07-16

4.  A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.

Authors:  Qunfeng Wu; Liya Pi; Thu Le Trinh; Chaohui Zuo; Man Xia; Yu Jiao; Zhouhua Hou; Sung Jo; William Puszyk; Kien Pham; David R Nelson; Keith Robertson; David Ostrov; Pranela Rameshwar; Chang Qing Xia; Chen Liu
Journal:  Mol Ther       Date:  2017-08-10       Impact factor: 11.454

5.  Curcumin inhibits the growth of liver cancer stem cells through the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway.

Authors:  Ji Wang; Chunying Wang; Gaofeng Bu
Journal:  Exp Ther Med       Date:  2018-01-29       Impact factor: 2.447

Review 6.  In search of liver cancer stem cells.

Authors:  Stephanie Ma; Kwok Wah Chan; Xin-Yuan Guan
Journal:  Stem Cell Rev       Date:  2008-07-29       Impact factor: 5.739

7.  Biomarker analysis of fucosylated kininogen through depletion of lectin reactive heterophilic antibodies in hepatocellular carcinoma.

Authors:  Mengjun Wang; Jiabin Shen; Harmin Herrera; Amit Singal; Charles Swindell; Lu Renquan; Anand Mehta
Journal:  J Immunol Methods       Date:  2018-08-23       Impact factor: 2.303

8.  Progenitor-derived hepatocellular carcinoma model in the rat.

Authors:  Jesper B Andersen; Roberto Loi; Andrea Perra; Valentina M Factor; Giovanna M Ledda-Columbano; Amedeo Columbano; Snorri S Thorgeirsson
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

9.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015

Review 10.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.